Every 8-K that NeuroBo Pharmaceuticals, Inc. (NRBO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NRBO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRBO filings page.
MetaVia Inc. Form 8-K — Regulation FD disclosure (Aug 6, 2025)
MetaVia furnished a press release announcing an extension of the 48 mg multiple ascending dose (MAD) cohort in the Phase 1 clinical trial of DA-1726 from 4 weeks to 8 weeks and reporting that a fifth weekly dose was administered to the first patient. DA-1726 is described as a novel dual oxyntomodulin (OXM) analog agonist acting at GLP1R and GCGR for obesity treatment.
- Date: August 6, 2025
- Action: Cohort duration extended to 8 weeks (from 4 weeks)
- Dosing update: Fifth weekly dose given to first patient
- Exhibit: Press release furnished as Exhibit 99.1 (information furnished, not filed)